DCT

1:26-cv-00427

UCB Inc v. Rubicon Research Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00427, D. Del., 04/14/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Rubicon, a foreign corporation, is subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiffs' NAYZILAM® (midazolam) nasal spray constitutes an act of infringement of four U.S. patents.
  • Technical Context: The technology relates to liquid pharmaceutical formulations, particularly for nasal drug delivery, designed to rapidly administer poorly water-soluble therapeutic agents for acute conditions like epileptic seizures.
  • Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a Notice Letter from Rubicon, dated March 2, 2026, which included a Paragraph IV certification against the four patents-in-suit. The certification states that Rubicon believes the patents are invalid, unenforceable, or will not be infringed by its proposed generic product. Plaintiffs' branded product, NAYZILAM®, holds orphan drug exclusivity until May 17, 2026.

Case Timeline

Date Event
2007-01-19 Priority Date for '033, '322, '432, and '495 Patents
2012-07-10 '033 Patent Issued
2014-08-19 '322 Patent Issued
2016-03-22 '432 Patent Issued
2017-06-27 '495 Patent Issued
2019-05-17 NAYZILAM® (NDA No. 211321) Approved by FDA
2026-03-02 Rubicon Sends Paragraph IV Notice Letter to Plaintiffs
2026-04-14 Complaint Filed
2026-05-17 NAYZILAM® Orphan Drug Exclusivity Expires

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,217,033 - "Methods and Compositions for the Delivery of a Therapeutic Agent"

  • Patent Identification: U.S. Patent No. 8,217,033, "Methods and Compositions for the Delivery of a Therapeutic Agent," issued July 10, 2012.

The Invention Explained

  • Problem Addressed: The patent describes the challenge of administering therapeutic agents that are poorly soluble in water, especially when a rapid systemic effect is needed '033 Patent, col. 1:21-38 Nasal delivery is a desirable non-invasive alternative to injection, but requires the drug to be dissolved in a small volume (e.g., less than 300 µL) to prevent it from draining away before absorption, a difficult task for sparingly soluble drugs '033 Patent, col. 2:6-16
  • The Patented Solution: The invention is a liquid pharmaceutical composition that uses an alkoxy-polyethylene glycol, such as methoxy-polyethylene glycol (mPEG), as a solvent '033 Patent, abstract This solvent system is able to dissolve a therapeutic agent like midazolam in a small volume suitable for nasal administration, while being less viscous and less irritating than prior art formulations, thereby enabling rapid absorption comparable to an intravenous injection '033 Patent, col. 3:28-44
  • Technical Importance: This formulation technology provides a method for rapid, non-invasive treatment of acute medical episodes, such as seizures, that would otherwise require administration by injection to achieve a fast onset of action '033 Patent, col. 2:35-37

Key Claims at a Glance

  • The complaint does not specify which claims are asserted, but alleges that the Defendant's notice letter did not contest infringement of any claim Compl. ¶40 Independent claim 1 is representative of the core invention.
  • Independent Claim 1 includes the following essential elements:
    • A liquid pharmaceutical composition formulated for intranasal administration;
    • comprising midazolam or a pharmaceutically acceptable salt thereof; and
    • comprising a methoxy-polyethylene glycol selected from the group consisting of methoxy-polyethylene glycol 350 and methoxy-polyethylene glycol 550.
      '033 Patent, col. 21:30-38
  • The complaint does not explicitly reserve the right to assert dependent claims, but makes a general allegation of infringement of "claims of the '033 Patent" Compl. ¶39

U.S. Patent No. 8,809,322 - "Methods and Compositions for the Delivery of a Therapeutic Agent"

  • Patent Identification: U.S. Patent No. 8,809,322, "Methods and Compositions for the Delivery of a Therapeutic Agent," issued August 19, 2014.

The Invention Explained

  • Problem Addressed: As a continuation of the same patent family, the '322 Patent addresses the same technical problem: the need for a non-invasive, rapidly absorbed formulation for poorly water-soluble drugs to treat acute conditions '322 Patent, col. 1:24-38
  • The Patented Solution: The patent describes a liquid composition for intranasal delivery of midazolam using a methoxy-polyethylene glycol solvent defined by its chemical structure. The use of this solvent system is claimed to create a low-viscosity, non-irritating, and rapidly bioavailable formulation suitable for nasal administration '322 Patent, abstract '322 Patent, col. 3:25-51
  • Technical Importance: The technology facilitates the replacement of inconvenient and painful injections with a simple nasal spray for acute therapies, expanding patient access and ease of use '322 Patent, col. 1:39-45

Key Claims at a Glance

  • The complaint does not identify specific asserted claims Compl. ¶49 Independent claim 1 is representative.
  • Independent Claim 1 includes the following essential elements:
    • A liquid pharmaceutical composition formulated for intranasal administration;
    • comprising a therapeutically effective amount of midazolam (or a salt thereof); and
    • comprising a methoxy-polyethylene glycol of Formula I, H3C-O-(CH2CH2O)n-H, where 'n' (the average number of oxyethylene repeating units) is a number in the range of 2 to 12.
      '322 Patent, col. 21:12-21
  • The complaint makes a general allegation of infringement against "claims of the '322 Patent" Compl. ¶49

U.S. Patent No. 9,289,432 - "Methods and Compositions for the Delivery of a Therapeutic Agent"

  • Patent Identification: U.S. Patent No. 9,289,432, "Methods and Compositions for the Delivery of a Therapeutic Agent," issued March 22, 2016.
  • Technology Synopsis: This patent, from the same family, describes liquid pharmaceutical compositions for the intranasal delivery of a benzodiazepine using a methoxy-polyethylene glycol solvent '432 Patent, abstract The formulation is designed to be low-viscosity and rapidly absorbed, providing an alternative to injection for acute conditions '432 Patent, col. 1:23-col. 2:15
  • Asserted Claims: The complaint does not specify claims Compl. ¶59 Independent claim 1 is representative, covering a liquid composition with a benzodiazepine and a methoxy-polyethylene glycol where 'n' is in the range of 2 to 12.
  • Accused Features: The accused feature is the formulation of Rubicon's proposed generic Midazolam nasal spray product (Compl. ¶¶1; Compl. ¶59).

U.S. Patent No. 9,687,495 - "Methods and Systems for the Delivery of a Therapeutic Agent"

  • Patent Identification: U.S. Patent No. 9,687,495, "Methods and Systems for the Delivery of a Therapeutic Agent," issued June 27, 2017.
  • Technology Synopsis: Unlike the other patents-in-suit, this patent claims a system for intranasal administration. The system comprises the combination of a nasal spray device and a liquid pharmaceutical composition disposed within it '495 Patent, abstract The composition itself contains a benzodiazepine and a methoxy-polyethylene glycol solvent '495 Patent, col. 21:44-53
  • Asserted Claims: The complaint does not specify claims Compl. ¶69 Independent claim 1 is representative.
  • Accused Features: The accused instrumentality is the combination of Rubicon's proposed generic Midazolam nasal spray formulation and the nasal spray device with which it will be sold and administered (Compl. ¶¶1; Compl. ¶69).

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendant Rubicon's proposed generic Midazolam nasal spray (5mg), identified in its filing as ANDA No. 221285 (the "ANDA Product") Compl. ¶1
  • Functionality and Market Context: The ANDA Product is a generic version of Plaintiffs' NAYZILAM® and is intended for the same indication: "the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures)" in epilepsy patients 12 years of age and older (Compl. ¶¶19; Compl. ¶30). The infringement alleged is statutory, arising from the act of filing the ANDA with a Paragraph IV certification seeking FDA approval to market the generic product prior to the expiration of the patents-in-suit Compl. ¶1 The complaint alleges that approval and sale of the ANDA Product will displace sales of NAYZILAM® Compl. ¶14

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element infringement analysis. The central allegation is that because Rubicon's ANDA Product is a generic version of NAYZILAM®, its composition and method of use will infringe the patents covering the branded product Compl. ¶1 The complaint further alleges that Rubicon's pre-suit Notice Letter did not contest that its ANDA Product would infringe at least one claim of each of the asserted patents Compl. ¶33 The following tables provide a representative analysis for the lead independent claim of the first two patents-in-suit, based on the general allegations.

'033 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A liquid pharmaceutical composition formulated for intranasal administration The ANDA Product is a liquid nasal spray. ¶1 col. 15:5-11
comprising: i) midazolam or a pharmaceutically salt thereof; The active pharmaceutical ingredient in the ANDA Product is midazolam. ¶1 col. 9:15
and ii) a methoxy-polyethylene glycol selected from the group consisting of methoxy-polyethylene glycol 350 and methoxy-polyethylene glycol 550. The complaint alleges infringement, which suggests the ANDA Product's formulation contains one of these specific excipients, but does not provide details on the excipients used. ¶39 col. 6:55-56

'322 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A liquid pharmaceutical composition formulated for intranasal administration The ANDA Product is a liquid nasal spray. ¶1 col. 15:5-11
comprising: a) a therapeutically effective amount of a therapeutic agent selected from midazolam, a pharmaceutically acceptable salt thereof or combinations thereof; The active pharmaceutical ingredient in the ANDA Product is midazolam. ¶1 col. 9:15-16
and b) a methoxy-polyethylene glycol of Formula I H3C-O-(CH2CH2O)n-H wherein n is a number in the range of 2 to 12. The complaint alleges infringement, suggesting the ANDA Product contains an mPEG excipient where the average number of repeating units ('n') is between 2 and 12, but does not provide specific details on the excipient. ¶49 col. 5:56-62
  • Identified Points of Contention:
    • Scope Questions: A central question will be whether the specific excipients used in Rubicon's ANDA Product fall within the scope of the claims. For the '033 Patent, this raises the question of whether Rubicon's formulation contains "methoxy-polyethylene glycol 350" or "methoxy-polyethylene glycol 550." For the '322 and '432 Patents, the question is whether the excipient has an average number of repeating units 'n' that falls "in the range of 2 to 12."
    • Technical Questions: The primary technical dispute will concern the precise chemical identity and properties of the solvent system in Rubicon's ANDA product. As the complaint was filed before Plaintiffs likely had full access to the ANDA, discovery will be required to establish the exact composition of the accused product Compl. ¶31

V. Key Claim Terms for Construction

The complaint does not offer a basis for claim construction analysis. However, based on the asserted patents, the following terms may be central to the dispute.

  • The Term: "methoxy-polyethylene glycol 350" (from '033 Patent, Claim 1)

  • Context and Importance: Practitioners may focus on this term because infringement will depend on whether the excipient in Rubicon's product is properly characterized as "mPEG 350." A dispute could arise over how much deviation from the "average" properties is permissible for a product to meet this limitation.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The claim uses the common commercial name for the substance, which could support an argument that the term should encompass what a person of ordinary skill in the art would understand that name to mean in the relevant time period.
    • Evidence for a Narrower Interpretation: The specification explicitly defines "mPEG 350" as "methoxy polyethylene glycol having an average molecular weight of about 350" and notes that in certain embodiments, the average number of repeating units, 'n', is 7.2 '033 Patent, col. 6:55-61 A party could argue this definition limits the term to excipients closely matching these specific properties.

  • The Term: "n is a number in the range of 2 to 12" (from '322 Patent, Claim 1 and '432 Patent, Claim 1)

  • Context and Importance: Practitioners may focus on this term because it creates a precise numerical boundary for infringement. The case may turn on whether the average number of repeating oxyethylene units in the excipient used in Rubicon's product falls within this exact range.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The claim language presents a clear, definite range. The specification provides a list of individual mPEG species with 'n' values from 2 through 14, suggesting the inventors contemplated a range of possibilities '322 Patent, col. 6:42-51
    • Evidence for a Narrower Interpretation: A party might argue that the effective scope should be tied to the specific embodiments that demonstrated success, such as mPEG 350 (n=7.2) and mPEG 550 (n=11.8) '322 Patent, col. 6:58-65 The prosecution history, if it contains arguments distinguishing prior art based on this range, could also be used to support a narrower interpretation.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval, Rubicon will induce infringement by marketing and distributing the ANDA Product with a product label and insert that instruct physicians, pharmacies, and end-users to administer the product in an infringing manner Compl. ¶43 Compl. ¶53 Compl. ¶63 Compl. ¶73
  • Willful Infringement: The complaint does not use the word "willful" but alleges that Rubicon had "actual knowledge" of each patent prior to submitting its ANDA Compl. ¶44 Compl. ¶54 Compl. ¶64 Compl. ¶74 It further alleges that Rubicon's conduct in certifying non-infringement or invalidity lacked "adequate justification," which renders the case "exceptional" under 35 U.S.C. § 285 Compl. ¶45 Compl. ¶55 Compl. ¶65 Compl. ¶75

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of factual determination: what is the precise chemical composition of the excipients in Rubicon's ANDA product? The outcome of the infringement analysis is entirely dependent on whether the solvent system in the accused generic product falls within the boundaries of the patent claims.
  • A second issue will be one of claim construction: how will the court define the scope of terms like "methoxy-polyethylene glycol 350" and the numerical range for "n" in "n is a number in the range of 2 to 12"? The resolution of this question will determine whether minor variations in the average molecular weight or structure of Rubicon's chosen excipient are sufficient to avoid infringement.
  • A third, and as yet undeveloped, issue will be patent validity: what will be Rubicon's basis for asserting that the patents are invalid? As this is a Hatch-Waxman case triggered by a Paragraph IV certification, Rubicon's defenses will likely include invalidity arguments (e.g., obviousness), the details of which will become central to the litigation as it proceeds.
Loading Complaint